Unless the overall treatment and services provided to schizophrenia patients in Finland is unique and especially protective—which the authors do not suggest—their claimed findings of lowered mortality rates for antipsychotic drug users are belied by a consistent body of evidence.
The study, reported in The Journal of the American Medical Association, "found no evidence of an association between the serotonin gene and the risk of depression, no matter what people’s life experience was."
Among the most damaging scientific evidence against the use of antipsychotic drugs is empirical evidence that they cause brain damage.
The FDA’s expanded marketing approval process for antipsychotics, highly toxic drugs, is unaffected by evidence uncovered by the US Justice Department showing that the studies submitted by drug manufacturers were often flawed, if not fraudulent.
"The story’s pretty clear, and pretty embarrassing for the profession of psychiatry, which has allowed itself to be led by marketing," says Dr. Robert Rosenheck, Yale.
Psychiatry’s leadership is scrambling and fumbling in its effort to explain why it’s collusion with industry for pay is okay.
This is a result of public awareness–thanks to information uncovered during litigation, by Sen. Charles Grassley’s investigative team, by whistleblowers, and the press!
Two news reports: Alaska Supreme Court decision and a JAMA report confirms that risk of violence among schizophrenia patients "was mostly confined to patients with substance abuse comorbidity."
Forbes Magazine reports "How one company turned a rejection into a thumbs up, and what it could mean for the drug industry as a whole."
The FDA has just approved the anitpsychotic drug, Fanapt (iloperidone) for adults with schizophrenia.
The drug, iloperidone, has a long history of failure. http://en.wikipedia.org/wiki/Iloperidone :
Grassley’s team has asked NAMI to disclose the specifics of its funding so that people with mental illness and their families, as well as the public and healthcare officials, can see for themselves how conflicted this advocacy group is.
The results suggest that the truth may have escaped the usual exclusion criteria. Underlying the commercial success of the new antipsychotics is evidence (usually suppressed) showing that these drugs are both harmful and ineffective even for their approved use.
